Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Proteon Inks Deal With Novartis
by Rick Mullin
March 16, 2009
| A version of this story appeared in
Volume 87, Issue 11
Proteon Therapeutics has granted Novartis an exclusive option to acquire it after the successful completion of a Phase II clinical study of PRT-201, a treatment developed by the Waltham, Mass.-based biopharma company for patients with renal disease undergoing surgery for arteriovenous fistula creation. The deal with Novartis, including acquisition payment and potential milestone payments, could be worth as much as $550 million. Proteon also completed a $38 million equity financing round led by MPM Capital. PRT-201 is currently in preliminary Phase IIa trials.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter